Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.

The stock's fall snapped a two-day winning streak.

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

This was the stock's second consecutive day of gains.

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...